DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 4 Harlan Krumholz - 4 Dr - 4 Sanjay Gupta - 4 Wegovy - 3 Eli Lilly - 3 it’s - 3 – - 2
Top related locs:
United States Baton Rouge , Louisiana Novo Mount Sinai South Korea
Top related orgs:
CNN - 4 CNN Health - 4 Yale University - 3 Yale New Haven Hospital - 2 Novo Nordisk - 2 American Heart Association - 2 drugmaker - 1 Nordisk - 1

Search resuls for: "Harlan Krumholz"


4 mentions found


☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
  + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +10 min
CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.
Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo
☆ Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
  + stars: | 2024-03-08 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +4 min
The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts. Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them. “This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added. More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event. Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.
Persons: CNN — Wegovy’s, –, Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, ” Organizations: CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, ”, CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations
☆ Tirzepatide: Weight loss drug helps significantly lower blood pressure in adults who are overweight or obese, study finds
  + stars: | 2024-02-05 | by ( Mira Cheng | ) edition.cnn.com   time to read: +6 min
The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.
Persons: —, Eli Lilly, ”, Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States
☆ For some cardiac patients with stents, long-term aspirin treatments might be on the way out
  + stars: | 2023-10-31 | by ( Giri Viswanathan | ) edition.cnn.com   time to read: +6 min
For years, medical professionals widely recommended regular aspirin to prevent heart problems, since aspirin can reduce blood clotting to prevent complications like heart attacks or strokes. Still, many health care professionals still consider aspirin to be beneficial for many patients who have heart problems or have a stent. Dropping aspirin also reduced the risk of severe bleeding by nearly 50% compared with patients on the combination therapy, said Mehran — without increasing the risk of cardiac complications. Given the results of her clinical trial and a growing amount of evidence suggesting that long-term aspirin may not be beneficial for acute coronary syndrome, Mehran prescribes a treatment plan without long-term aspirin for her own patients. Aspirin remains ‘an essential therapy’However, experts agree that aspirin remains a beneficial medication for heart conditions.
Persons: ’ ”, Roxana Mehran, Mehran, ” Mehran, Aspirin, Dr, Harlan Krumholz, ticagrelor, Sanjay Gupta, ” Organizations: CNN, Icahn School of Medicine, World Health Organization, American College of Cardiology, American Heart Association, United States Preventive Services Task Force, Yale School of Medicine, CNN Health Locations: Mount Sinai, United States, South Korea
0 next >>
Total: 4